Skip to main content
Equibles
SGMOQ logo

SGMOQ · Sangamo Therapeutics, Inc · Metrics

Track SGMOQ — free

Use SGMOQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SGMOQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.10 -0.01 (-8.17%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged May 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”
View the 10-Q filed May 14, 2026
Market Cap
$41.43M
Shares
414.29M
Volume · Oct 19 1.9M Avg daily vol (3M) 2.58M

SGMOQ metrics

67 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.10
Market cap
$41.43M

Price action

20 metrics
Price change (1W)
-25.4%
Price change (30D)
-22.0%
Price change (3M)
+57.4%
Price change (6M)
-57.6%
Price change (YTD)
-73.8%
Price change (1Y)
-82.8%
Trailing year
Price change (5Y)
-98.7%
52-week high
$0.68
52-week low
$0.04
Change from 52-week high
-83.8%
Change from 52-week low
+175.5%
Annualized volatility
161.6%
Annualized volatility (3M)
114.9%
Beta
2.0
RSI (14D)
28.1
Price vs SMA 50
-26.0%
Price vs SMA 200
-51.3%
Avg volume (3M)
2.60M
Relative volume
0.8
Average dollar volume
$351,068

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
414.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.5×
reciprocal yield 192.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 75.8%
P / book
—
FCF yield
-198.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-270.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.6×
reciprocal yield 27.8%
EV / revenue historical average (5Y)
4.5×
reciprocal yield 22.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-14

Profitability

9 metrics
Gross margin
—
Operating margin
-357.5%
Trailing 12 months
Net margin
-356.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$123.56M
Net income (TTM)
−$123.33M
Trailing 12 months
Diluted EPS (TTM)
$-0.38
FCF margin
-261.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.04

Growth

11 metrics
Revenue growth YoY
-77.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$34.56M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+76.9%
Year over year · more shares
Revenue CAGR (3Y)
-29.2%
Revenue CAGR (5Y)
-19.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-205.7%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$119.90M
Free cash flow (TTM)
−$90.46M
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$27.59M
Latest balance sheet
Cash & equivalents
$27.59M
Total assets
$59.97M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$90.34M
Capital expenditures (TTM)
$115,000
R&D (TTM)
$113.23M
SG&A (TTM)
—
Stock compensation (TTM)
$7.47M
R&D / revenue
327.7%
Stock compensation / revenue
21.6%

Ownership (13F)

3 metrics
13F filers
7
13F filer change QoQ
-107
Institutional ownership
0.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
2.2%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
50 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1001233 CUSIP 800677106 Visit website Investor relations